Dyadic International DYAI
NASDAQ DYAI
$0.38 +0.04 (+11.76%)
At close: Nov 9, 2026 · 4:00 PM EST

Dyadic International (DYAI) Times Interest Earned (2024 - 2026)

Updated

Dyadic International's Times Interest Earned was -17.43 in Q1 2026, compared with -17.63 a year earlier.

Analysis

Dyadic International (DYAI) Times Interest Earned (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, Dyadic International's Times Interest Earned was -15.71 through Mar 31, 2026; for FY2025, it was -15.78.

  • In earlier years, Times Interest Earned was -13.79 in FY2024.
  • Quarterly Times Interest Earned has moved between -65.49 (Q1 2024) and -1.58 (Q3 2024) over five years.
  • Per Business Quant data, DYAI's Times Interest Earned in the three quarters before Q1 2026 was -13.43 (Q4 2025), -16.87 (Q3 2025) and -15.19 (Q2 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Times Interest Earned (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn -
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 28.50
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn -
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn -
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn 9.20
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 5.68
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 12.87
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn -
10 Dyadic International 13.85 Mn 7.25 Mn - -17.43
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.43
Dec 31, 2025 -13.43
Sep 30, 2025 -16.87
Jun 30, 2025 -15.19
Mar 31, 2025 -17.63
Dec 31, 2024 -12.12
Sep 30, 2024 -1.58
Jun 30, 2024 -14.48
Mar 31, 2024 -65.49
API Access

Dyadic International Times Interest Earned API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=times-interest-earned&ticker=DYAI&period=max&api_key=YOUR_API_KEY